Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL149462 | 0.93 | USP2 (0.61) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| SCHEMBL28914 | 0.93 | USP2 (0.61) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| SCHEMBL28138343 | 0.93 | USP2 (0.61) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| SCHEMBL21057 | 0.93 | USP2 (0.61) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| Water SCHEMBL3908933 | 0.91 | USP2 (0.59) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| Ammonia Solution, Strong SCHEMBL2719059 | 0.91 | USP2 (0.59) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| Sulfuric Acid SCHEMBL2221135 | 0.86 | USP2 (0.53) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| Sulfuric Acid SCHEMBL3238445 | 0.86 | USP2 (0.53) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| Propylamine SCHEMBL13737874 | 0.84 | USP2 (0.52) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| Phosphoric Acid SCHEMBL30301188 | 0.81 | PDE4A (0.50) | USP2SLCO1B1LMNAL3MBTL1PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200113981-A1 | CNS DELIVERY OF THERAPEUTIC AGENTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-04-16 | — | — | US | disclosed |
| EP-2830642-A1 | SUBCUTANEOUS ADMINISTRATION OF IDURONATE- 2-SULFATASE | Shire Human Genetic Therapies, Inc. (US) | 2015-02-04 | — | — | EP | disclosed |
| EP-2793933-A2 | TREATMENT OF COGNITIVE IMPAIRMENT OF HUNTER SYNDROME BY INTRATHECAL DELIVERY OF IDURONATE-2-SULFATASE | Shire Human Genetic Therapies, Inc. (US) | 2014-10-29 | — | — | EP | disclosed |
| WO-2013148277-A1 | SUBCUTANEOUS ADMINISTRATION OF IDURONATE- 2-SULFATASE | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2013-10-03 | — | — | WO | disclosed |
| WO-2013096912-A2 | TREATMENT OF COGNITIVE IMPAIRMENT OF HUNTER SYNDROME BY INTRATHECAL DELIVERY OF IDURONATE-2-SULFATASE | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2013-06-27 | — | — | WO | disclosed |
| EP-2588130-A1 | CNS DELIVERY OF THERAPEUTIC AGENTS | Shire Human Genetic Therapies, Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| EP-2585104-A2 | METHODS AND COMPOSITIONS FOR CNS DELIVERY OF ARYLSULFATASE A | Shire Human Genetic Therapies, Inc. (US) | 2013-05-01 | — | — | EP | disclosed |
| WO-2011163648-A1 | CNS DELIVERY OF THERAPEUTIC AGENTS | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2011-12-29 | — | — | WO | disclosed |
| WO-2011163650-A2 | METHODS AND COMPOSITIONS FOR CNS DELIVERY OF ARYLSULFATASE A | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2011-12-29 | — | — | WO | disclosed |
| WO-2005113765-A2 | METHODS OF ACTIVATION OF SULFATASES AND METHODS AND COMPOSITIONS OF USING THE SAME | BIOMARIN PHARMACEUTICAL INC. (US) | 2005-12-01 | — | — | WO | disclosed |